WA-PATTERN-COMPUTER
Pattern Computer,® Inc . (PCI) has developed a novel test for near real-time (15 sec) diagnosis of SARS-CoV-2 infections. In contrast with widely used antibody and PCR tests, which take at least 15 minutes to produce results, and require scarce reagents to process, the newly developed PCI method enables high-volume throughput of tests without requiring chemical reagents at difficult to service locations, such as company entrances, event venues, court houses, state and federal facilities, TSA screening areas and ports of entry.
“Having a simple, fast, easy to administer, high accuracy COVID-19 test will be critical for TSA and the airline carriers to increase passenger safety and confidence, as carriers deal with rising passenger loads and increased health security requirements,” said Bob Edwards, former CIO for United Airlines. “Pattern Computer’s new system appears to meet that need.”
Developed using the Pattern Discovery Engine™ (PDE) comprised of proprietary software methods and specially configured hardware, the initial results suggest this low-cost, high-volume COVID-19 test could create new opportunities for reducing transmission risk in high-headcount, high-density entertainment venues, large-scale events, office buildings, trains, busses, aircraft, and subways.
“As the world enters the next cycles of COVID lockdowns and flareups, there will be a pressing need for the companion technology to vaccines – the ability to detect true positive infections, and simultaneously reduce the incidence of false positives, coupled with higher reliability rates, delivered in real time. These are the required characteristics of a regimen of testing that will enable better containment of future outbreaks. The Pattern Computer team was able to apply the proven abilities of the Pattern Discovery Engine to take on this daunting challenge. We wanted to create a high-performance, extremely accurate, reagent-free, real-time alternative for testing in the world’s most important venues. This combination of proprietary hardware and software appears capable of meeting that critical need,” according to Mark R. Anderson, CEO of Pattern Computer.
Pattern Computer’s new test has been used to analyze data from symptomatic and asymptomatic patients between 10 and 80 years old. The reported balanced accuracy of the new test is >96%. The aspects of the testing that are worth noting: the Pattern team has been working on the problem for a few months, and is working with a dataset that numbers in the hundreds of data points. Competing organizations and teams have been working on the same problem for over a year with millions of data points, to only deliver tests that are 97% accurate.
The results from the Pattern tests are competitive with the performance of antibody tests currently in the market, which under ideal conditions (3 weeks after onset of symptoms) reports a balanced accuracy of 95%1 . In contrast to antibody tests, which are highly sensitive to timing--only 30% of people infected with SARS-CoV-2 tests positive 1 week after the onset of symptoms--the performance of PCI diagnosis is agnostic regarding how long the patient has been symptomatic.
“Pattern Computer has rapidly developed a reagent free SARS-CoV-2 diagnostic platform with an impressive level of accuracy. This technology has the potential to alter the landscape of disease diagnostics. Currently, they are focused on COVID-19, but their approach is applicable, in principle, to any disease. I suspect that, in the new future, as we walk through TSA security at an airport, part of the screen will be for infectious diseases. The implications of this technology for public safety and health, especially disease surveillance, are enormous,” said Prof. J. Ben Brown, UC Berkeley & Lawrence Berkeley National Laboratory.
PCI has built an initial model that predicts COVID-19 status (as determined by multi-target RT-PCR) of a patient based on its proprietary hardware measurements. Sensitivity and specificity are computed with 5-fold cross-validation.
PCI expects that as more data points are added to the PCI data base, particularly data from non-infected individuals, its technology will be able to match or exceed RT-PCR for accurate SARS-CoV-2 infection detection, with the reduced result time of 20 seconds rather than the current standard wait time of 30 minutes or more2 .
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward-looking statements” for purposes of applicable securities laws and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
For more information on Pattern Computer Inc., visit: www.patterncomputer.com
For more information about Mark Anderson, visit: www.patterncomputer.com/founders/
Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
_________________________________________________
1
Antibody tests for identification of current and past infection with SARS‐CoV‐2 - Deeks, JJ - 2020 | Cochrane Library
, https://doi.org/10.1002/14651858.CD013652
, June 25, 2020
2
Covid-19: Bosch develops “fastest” PCR test in the world (msn.com)
, https://www.msn.com/en-ae/news/other/covid-19-bosch-develops-fastest-pcr-test-in-the-world/ar-BB1aNLVB
, August 11, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005847/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 01:55:00 CEST | Press release
Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator’s Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a Type-II variation application for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU) by end of year Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moder
MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem25.10.2025 10:24:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution, has entered into an exclusive worldwide multi-billion-dollar joint venture with global sports icon and undefeated UFC champion Khabib Nurmagomedov (29-0) to create a first-of-its-kind regulated ecosystem connecting global finance, sports and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251025540563/en/ MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem The partnership will culminate in the creation of a multi-billion-dollar joint venture, MultiBank Khabib LLC, uniting two global powerhouses: MultiBank Group, a leader in regulated financial excellence, and Khabib Nurmagomedov, undefeated in the octagon and whose influence extends far beyond sport.The company will operate from MultiBank Group’s headquarters in Dubai, building
Altimetrik Completes Acquisition of SLK Software, Uniting Strengths to Unlock Value through AI-First and Digital Enablement24.10.2025 18:57:00 CEST | Press release
Altimetrik today announced the successful completion of its acquisition of SLK Software, marking a major milestone in the company’s journey to build a digital engineering powerhouse. As part of this transition, SLK Software will now operate under its new identity as “SLK, an Altimetrik company”. The integration brings together Altimetrik’s AI-first, data-led innovation capabilities with SLK’s strength in Intelligent Enterprise, Digital Operations, Intelligent Infrastructure and Automation and Quality Engineering - spanning the entire digital enablement value chain from strategy and design to engineering and managed services. Anchored in a Practitioner-Led approach, the unified organization merges deep domain expertise with modern platforms and digital operating models to deliver bite-size, outcome-focused execution that accelerates time-to-value. “I am thrilled to officially welcome the SLK team to Altimetrik, bringing together two organizations driven by purpose, innovation, and an un
Andersen Consulting samarbejder med Acronotics om at udbygge AI-styrede digitale transformationskapaciteter24.10.2025 17:55:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Acronotics, et hurtigt voksende digitalt konsulentfirma med hovedsæde i Storbritannien og afdelinger i USA og Indien. Som specialist i AI-drevet forretningstransformation samarbejder Acronotics med Fortune 500-virksomheder om at fremskynde den digitale transformation ved hjælp af kunstig intelligens. Virksomheden har dyb ekspertise inden for produktion, bankvirksomhed og finansielle tjenester, detailhandel, hurtigt omsættelige forbrugsgoder og højteknologiske industrier med stærkt fokus på AI/ML, generativ AI og RPA-teknologi. Acronotics leverer end-to-end-tjenester, herunder design, udvikling og implementering af Agentic AI og RPA-baserede procesautomatiseringsløsninger. Ved hjælp af sin egenudviklede automatiserede digitale medarbejderstyringsplatform, Radium.ai, hjælper virksomheden sine kunder med at administrere og overvåge deres digitale arbejdsstyrke effek
LambdaTest Unveils AI-Powered Web Scanner for Scalable Visual and Accessibility Testing24.10.2025 17:00:00 CEST | Press release
New browser-based solution empowers teams to detect visual bugs and ensure accessibility compliance at scale LambdaTest, a GenAI-native quality engineering platform, today announced the launch of LambdaTest Web Scanner, an advanced browser-based tool combining Visual UI Regression Testing and WCAG-compliant Accessibility Testing. It enables teams to identify and resolve visual and accessibility issues across web applications with unparalleled speed and precision. LambdaTest Web Scanner combines key features to streamline visual and accessibility testing. It offers Visual UI Regression Testing with SmartUI technology, enabling automated scans that detect layout changes and design mismatches across browsers and screen resolutions. It also supports WCAG-compliant Accessibility Testing, identifying violations and providing recommendations for inclusivity. The tool enables cross-browser and responsive testing across multiple browsers and 200+ mobile viewports, while smart scheduling allows
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
